52,563 Shares in OptimizeRx Corp. $OPRX Bought by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new position in OptimizeRx Corp., purchasing 52,563 shares valued at approximately $455,000 in the first quarter.
• Other hedge funds have also increased their stakes in OptimizeRx, with notable acquisitions including Invesco Ltd. investing approximately $2.54 million during the same period.
• Recent analyst upgrades have positively impacted OptimizeRx's stock, with JMP Securities raising their price target from $14.00 to $20.00 and classifying it as a "market outperform."

Nuveen LLC acquired a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 52,563 shares of the company's stock, valued at approximately $455,000. Nuveen LLC owned about 0.28% of OptimizeRx at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of OptimizeRx in the first quarter worth about $112,000. Invesco Ltd. bought a new position in OptimizeRx in the first quarter worth approximately $2,542,000. Charles Schwab Investment Management Inc. increased its holdings in OptimizeRx by 30.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,228 shares of the company's stock worth $470,000 after purchasing an additional 12,676 shares during the period. Blair William & Co. IL raised its position in OptimizeRx by 4.9% during the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after purchasing an additional 29,648 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of OptimizeRx by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company's stock worth $775,000 after buying an additional 1,826 shares during the period. Institutional investors own 76.47% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on OPRX shares. B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Stifel Nicolaus upped their price objective on OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. JMP Securities lifted their target price on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.81.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded down $0.23 during trading on Wednesday, hitting $17.56. 403,169 shares of the company's stock were exchanged, compared to its average volume of 334,950. The stock has a market capitalization of $326.09 million, a price-to-earnings ratio of -32.52 and a beta of 1.20. The business has a 50-day simple moving average of $15.18 and a 200-day simple moving average of $11.66. OptimizeRx Corp. has a 52-week low of $3.78 and a 52-week high of $19.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.